BEBT-607

BEBT-607 is an orally bioavailable small molecule inhibitor targeting the oncogenic KRAS G12C mutation, which is found in various solid tumors such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. By selectively inhibiting the mutant KRAS G12C protein, BEBT-607 disrupts downstream signaling pathways involved in tumor growth and survival. Preclinical studies have shown that BEBT-607 has a novel structure with stronger target inhibitory activity and higher oral exposure compared to other agents like sotorasib. It is currently being evaluated in Phase I clinical trials for patients with advanced or metastatic solid tumors harboring KRAS G12C mutations who have failed standard therapies[1][2][3][4][5].

Other names

KRAS G12C inhibitor BEBT-607